Medidata Solutions, Inc. (NASDAQ:MDSO) had its price objective trimmed by Wells Fargo & Company from $83.00 to $80.00 in a research note released on Friday, October 27th. The brokerage currently has a market perform rating on the stock.
MDSO has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Medidata Solutions from a hold rating to a sell rating in a report on Friday, July 21st. KeyCorp restated a buy rating and set a $86.00 price target on shares of Medidata Solutions in a report on Sunday, September 17th. Jefferies Group LLC restated a hold rating and set a $78.00 price target on shares of Medidata Solutions in a report on Tuesday, August 22nd. Citigroup Inc. reiterated a buy rating and issued a $95.00 target price (up previously from $94.00) on shares of Medidata Solutions in a report on Monday, July 24th. Finally, Morgan Stanley lifted their target price on shares of Medidata Solutions from $74.00 to $86.00 and gave the company an overweight rating in a report on Thursday, July 20th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $84.25.
Medidata Solutions (NASDAQ:MDSO) traded up $0.73 during trading hours on Friday, reaching $65.69. 516,200 shares of the company’s stock traded hands, compared to its average volume of 548,634. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.37 and a current ratio of 1.29. Medidata Solutions has a one year low of $47.77 and a one year high of $85.92. The stock has a market capitalization of $3,797.62, a price-to-earnings ratio of 78.26, a price-to-earnings-growth ratio of 3.91 and a beta of 1.78.
Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Thursday, October 26th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.02. The business had revenue of $140.08 million for the quarter, compared to analyst estimates of $141.27 million. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.28 EPS. research analysts predict that Medidata Solutions will post 0.77 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/12/wells-fargo-company-lowers-medidata-solutions-inc-mdso-price-target-to-80-00.html.
In related news, COO Michael L. Capone sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $74.53, for a total transaction of $372,650.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Tarek Sherif sold 200,000 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $68.76, for a total transaction of $13,752,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 220,000 shares of company stock worth $15,190,400. 5.80% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the company. Fortaleza Asset Management Inc. acquired a new stake in shares of Medidata Solutions in the third quarter worth $155,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Medidata Solutions by 10.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock worth $171,000 after acquiring an additional 208 shares in the last quarter. Parametrica Management Ltd acquired a new stake in shares of Medidata Solutions in the second quarter worth $216,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Medidata Solutions in the second quarter worth $227,000. Finally, ETF Managers Group LLC purchased a new position in shares of Medidata Solutions in the second quarter valued at $233,000. 97.52% of the stock is owned by institutional investors.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.